

Cavit Boz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7639088/publications.pdf>

Version: 2024-02-01

121
papers

5,681
citations

109137

35
h-index

85405

71
g-index

127
all docs

127
docs citations

127
times ranked

5673
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
2	Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey. Asian Biomedicine, 2022, 16, 23-30.	0.2	0
3	Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression. Arquivos De Neuro-Psiquiatria, 2022, 80, 168-172.	0.3	1
4	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	1.4	2
5	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	1.7	3
6	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
7	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	1.4	7
8	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	1.4	5
9	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	1.4	3
10	Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study. Noropsikiyatri Arsivi, 2021, 58, 257-260.	0.2	1
11	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
12	The Role of Thrombo-Inflammatory Biomarkers in the Prognosis of Cerebral Venous Sinus Thrombosis. Current Neurovascular Research, 2021, 18, 237-243.	0.4	7
13	Determinants of disability development in patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2021, 79, 489-496.	0.3	5
14	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.5	15
15	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. CNS Drugs, 2021, 35, 1097-1106.	2.7	7
16	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
17	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	2.6	21
18	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.3	9
20	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
21	A Case Report of Acute Disseminated Encephalomyelitis in a Pregnant Woman After COVID-19 Infection. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2021, 27, 49-51.	0.1	1
22	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
23	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
24	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
25	Methylprednisolone Concentrations in Breast Milk and Serum of Patients with Multiple Sclerosis Treated with IV Pulse Methylprednisolone. <i>Clinical Neurology and Neurosurgery</i> , 2020, 197, 106118.	0.6	10
26	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	4.5	21
27	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
28	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
29	Decreased second to fourth digit ratios in female multiple sclerosis patients. <i>Early Human Development</i> , 2020, 144, 105039.	0.8	3
30	Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database. <i>Human Mutation</i> , 2020, 41, e7-e45.	1.1	10
31	“Is RLS a harbinger and consequence of MS?: Striking results of the “RELOMS-T” study”. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102055.	0.9	6
32	Electrophysiological, functional and histopathological assessments of high dose melatonin on regeneration after blunt sciatic nerve injury. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 370-377.	0.8	5
33	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. <i>Neurology and Therapy</i> , 2020, 9, 55-66.	1.4	18
34	The COVID-19 from Neurological Overview. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2020, 26, 58-108.	0.1	7
35	Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101376.	0.9	4
36	Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 94-99.	0.9	15

#	ARTICLE	IF	CITATIONS
37	The Efficacy of Acupuncture in the Treatment of Bell's Palsy Sequelae. JAMS Journal of Acupuncture and Meridian Studies, 2019, 12, 122-130.	0.3	18
38	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	0.9	71
39	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	0.9	35
40	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55
41	A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial. Noropsikiyatri Arsivi, 2019, 56, 253-257.	0.7	1
42	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	0.9	0
43	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	0.9	22
44	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
45	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	1.4	37
46	Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1205-1211.	1.4	23
47	Silent lesions on MRI imaging " Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	1.4	8
48	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.3	22
49	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	4.5	20
50	Pregnancy-induced Susac Syndrome: A Case Report. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2018, 2018, 70-71.	0.1	1
51	Evaluating Treatment Decision for Multiple Sclerosis: Involving Patients and Real Life. Noropsikiyatri Arsivi, 2018, 55, S10-S14.	0.2	1
52	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
53	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	0.9	49
54	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134

#	ARTICLE	IF	CITATIONS
55	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
56	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	4.9	472
57	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
58	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
59	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94
60	Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2016, 2016, 1-7.	0.4	9
61	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
62	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	0.8	33
63	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
64	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
65	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	0.5	5
66	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort. <i>Neurologist</i> , 2015, 20, 61-66.	0.4	8
67	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
68	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	1.7	43
69	<sc>BREMSO</sc>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989.	1.7	32
70	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
71	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
72	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	1.1	122

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

73	Evaluation of Temperament and Character Features as Risk Factors for Depressive Symptoms in		
----	---	--	--

#	ARTICLE	IF	CITATIONS
91	Basilar artery occlusion in migraine-like headache: a possible triggering effect of sumatriptan. <i>Neurological Sciences</i> , 2012, 33, 125-128.	0.9	9
92	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
93	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	1.1	166
94	Electrodiagnosis of carpal tunnel syndrome in patients with diabetic polyneuropathy. <i>Clinical Neurophysiology</i> , 2011, 122, 1463-1469.	0.7	54
95	VEMP responses are not affected in non-insulin-dependent diabetes mellitus patients with or without polyneuropathy. <i>Acta Oto-Laryngologica</i> , 2008, 128, 768-771.	0.3	28
96	Erratum to "Reduced effectiveness of long-term interferon- β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study" by C Boz, J Oger, E Gibbs, SE Grossberg and the Neurologists of the UBC MS Clinic. <i>Multiple Sclerosis</i> 2007; 13: 1127-1137. <i>Multiple Sclerosis Journal</i> , 2008, 14, 575-575.	1.4	0
97	Reduced effectiveness of long-term interferon- β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1127-1137.	1.4	38
98	Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 534-542.	1.0	30
99	Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 124-128.	0.6	60
100	Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 618.	0.6	0
101	Economic impact of primary headaches in Turkey: a university hospital based study: part II. <i>Journal of Headache and Pain</i> , 2006, 7, 75-82.	2.5	22
102	Neuromyelitis Optica in Patients With Myasthenia Gravis Who Underwent Thymectomy. <i>Archives of Neurology</i> , 2006, 63, 851.	4.9	93
103	The Impact of Migraine on Epilepsy: A Prospective Prognosis Study. <i>Cephalalgia</i> , 2005, 25, 528-535.	1.8	59
104	Benign Acute Childhood Myositis. <i>Medical Principles and Practice</i> , 2004, 13, 227-229.	1.1	15
105	Temperament and character profiles of patients with tension-type headache and migraine. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 536-543.	1.0	48
106	Transient tic disorder following carbon monoxide poisoning. <i>Journal of Neuroradiology</i> , 2004, 31, 231-233.	0.6	6
107	Guillain-Barré syndrome during treatment with interferon β for hepatitis B. <i>Journal of Clinical Neuroscience</i> , 2004, 11, 523-525.	0.8	8
108	Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements. <i>Clinical Neurology and Neurosurgery</i> , 2004, 106, 294-299.	0.6	107

#	ARTICLE	IF	CITATIONS
109	Ocular Myasthenia Gravis Associated With X-Linked Recessive Spinal and Bulbar Muscular Atrophy. <i>Journal of Clinical Neuromuscular Disease</i> , 2004, 5, 115-118.	0.3	5
110	Isolated hypoglossal nerve palsy in a child. <i>Turkish Journal of Pediatrics</i> , 2004, 46, 101-3.	0.3	3
111	The efficacy and safety of dipyron (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. <i>Functional Neurology</i> , 2004, 19, 197-202.	1.3	19
112	Acute disseminated encephalomyelitis after bee sting. <i>Neurological Sciences</i> , 2003, 23, 313-315.	0.9	45
113	Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients. <i>Journal of Headache and Pain</i> , 2003, 4, 72-78.	2.5	14
114	Central nervous system involvement in autoimmune polyglandular syndrome. <i>Clinical Neurology and Neurosurgery</i> , 2003, 105, 102-104.	0.6	11
115	Evaluation of Plasma Endothelin-1 Levels in Patients with Cerebral Infarction. <i>Angiology</i> , 2002, 53, 77-82.	0.8	14
116	X-linked spinal and bulbar muscular atrophy without proximal atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2002, 105, 14-17.	0.6	3
117	Relationship between major depression and heart rate variability.. <i>Psychiatry Research</i> , 2002, 113, 139-149.	1.7	274
118	Cerebral infarction following intravenous immunoglobulin therapy for Guillain-Barre syndrome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2001, 10, 290-292.	0.7	8
119	Status Epilepticus After Stroke. <i>Stroke</i> , 2001, 32, 1169-1172.	1.0	126
120	Baclofen is effective in intractable hiccups induced by brainstem lesions. <i>Neurological Sciences</i> , 2001, 22, 409-409.	0.9	12
121	Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2000, 9, 176-180.	0.7	6